RedHill Biopharma Ltd., a biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of approximately 4.7 million American Depositary Shares (“ADSs”) for gross proceeds of approximately $15.5 million, before deducting underwriting discounts and commissions and ...